We overcome critical limitations in regenerative biomaterials with CRISPR-edited, zero-immunogenicity ECM. Our enzymatic decellularization process preserves 95% of native collagen/elastin structures while eliminating immune risks.
As pioneers in microfluidic manufacturing (China’s first operational line), we produce perfectly uniform microspheres (30-80μm ±0.6 dispersity) at 90% yield – 4.5× industry average
Production & Capacity
—Scalable, Flexible Manufacturing Engineered for Partnership
